Patents by Inventor Alvin H. Schmaier

Alvin H. Schmaier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
    Patent number: 7879792
    Abstract: The invention relates to synthetic peptide analogs of D-Arg-Oic-Pro-Gly-Phe and methods of their use to inhibit human platelet aggregation, thrombosis and cell activation mediated by PAR1 and PAR4.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: February 1, 2011
    Assignee: The Regents of the University of Michigan
    Inventors: Alvin H. Schmaier, Henry I. Mosberg, Fernanda F. Marques, John Hilfinger
  • Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
    Patent number: 7074765
    Abstract: The invention relates to compounds and methods for inhibiting human platelet aggregation, thrombosis and cell activation mediated by PAR1 and PAR4 using peptide analogs of Arg-Pro-Pro-Gly-Phe that contain one or more amino acid substitutions. The invention also includes screening methods for identifying compounds that inhibit thrombin mediated activities.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: July 11, 2006
    Assignees: The Regents of the University of Michigan, Thromgen, Inc.
    Inventors: Alvin H. Schmaier, Ahmed A. K. Hasan
  • Bradykinin analogs as selective inhibitors of cell activation
    Patent number: 6982249
    Abstract: The present invention provides bradykinin peptide analogs, compositions, and methods of inhibiting thrombin-induced platelet and other cell activation. The bradykinin analogs comprise single or multiple peptide segments. The invention also provides a method for identifying compounds that selectively inhibit thrombin-induced platelet and other cell activation.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: January 3, 2006
    Assignee: The Regents of the University of Michigan
    Inventors: Alvin H. Schmaier, Ahmed A. K. Hasan
  • Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
    Publication number: 20040220110
    Abstract: The invention relates to compounds and methods for inhibiting human platelet aggregation, thrombosis and cell activation mediated by PAR1 and PAR4 using peptide analogs of Arg-Pro-Pro-Gly-Phe that contain one or more amino acid substitutions. The invention also includes screening methods for identifying compounds that inhibit thrombin mediated activities.
    Type: Application
    Filed: May 1, 2003
    Publication date: November 4, 2004
    Inventors: Alvin H. Schmaier, Ahmed A.K. Hasan
  • Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1
    Patent number: 6544750
    Abstract: The invention relates to inhibiting human platelet aggregation, thrombosis and cell activation mediated by PAR1 with peptide analogs corresponding to those of Formula I and II, wherein Formula I is: Arg-Gly-Lys-Z4-Cys wherein: Z4 is any naturally occurring amino acid, excluding cysteine; and wherein Formula II is: Arg-Gly-Asp-Z4-Cys wherein: Z4 is any naturally occurring amino acid, excluding cysteine.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: April 8, 2003
    Assignees: Thromgen, Inc., Regents of the University of Michigan
    Inventors: Alvin H. Schmaier, Ahmed A. K. Hasan
  • Bradykinin analogs as selective thrombin inhibitors
    Patent number: 6143719
    Abstract: Thrombin-induced and ADP-induced platelet and other cell activation is inhibited without affecting thrombin's other proteolytic activity by administration of a bradykinin sequence related analogous peptide. Bradykinin analogs are peptides to which substitutions, additions or deletions have been made to the first four amino acids of the amino acid sequence of native bradykinin. The bradykinin analogs described inhibit .alpha.-thrombin-induced and ADP-induced platelet activation and secretion, inhibit .alpha.-thrombin-induced calcium mobilization, and prevent .alpha.-thrombin from cleaving its platelet receptor. The bradykinin analogs may comprise single- or multiple-chain peptides.
    Type: Grant
    Filed: July 16, 1996
    Date of Patent: November 7, 2000
    Assignee: The Regents of the University of Michigan
    Inventors: Alvin H. Schmaier, Ahmed A. K. Hasan
  • Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
    Patent number: 5472945
    Abstract: The release of bradykinin into the circulatory system is potentiated by administration of a polypeptide having an amino acid sequence corresponding to domain 3 of the human kininogen heavy chain. The polypeptide competitively inhibits the binding of high and low molecular weight kininogen to platelets and other cells which protect the kininogens from kallikrein cleavage, thereby increasing the level of bradykinin in the cirulation. The resulting in vivo effect is an intravascular elevation of bradykinin and concomitant lowering of blood pressure. The domain 3 polypeptide also inhibits thrombin-induced platelet and endothelial cell activation.
    Type: Grant
    Filed: February 9, 1994
    Date of Patent: December 5, 1995
    Assignee: Temple University- of the Commonwealth System of Higher Education
    Inventors: Alvin H. Schmaier, Yongping Jiang
  • Method for detecting human kininogen using monoclonal antibodies thereto
    Patent number: 5047323
    Abstract: Two novel cell lines, ATCC #HB-8963 and ATCC #HB-8964 produce monoclonal antibody to human kininogen. One of the antibodies specifically recognizes the heavy chain of high and low molecular weight kininogen (the later protein is identical to alpha cysteine protease inhibitor). The other antibody recognizes the light chain of high molecular weight kininogen. The hybridomas are formed by fusing spleen cells from immunized BALB/c AnSkh mice with P3X63Ag8 or SP2/0-Ag14 myeloma cells. Diagnostic, therapeutic and biochemical uses of the monoclonal antibodies are provided.
    Type: Grant
    Filed: October 30, 1989
    Date of Patent: September 10, 1991
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Robert W. Colman, Alvin H. Schmaier
  • Monoclonal antibodies to human kininogen and methods of preparing same
    Patent number: 4908431
    Abstract: Two novel cell lines, ATCC #HB-8963 and ATCC #HB-8964 produce monoclonal antibody to human kininogen. One of the antibodies specifically recognizes the heavy chain of high and low molecular weight kininogen (the later protein is identical to alpha cysteine protease inhibitor). The other antibody recognizes the light chain of high molecular weight kininogen. The hybridomas are formed by fusing spleen cells from immunized BALB/c AnSkh mice with P3X63Ag8 or SP2/0-Ag14 myeloma cells. Diagnostic, therapeutic and biochemical uses of the monoclonal antibodies are provided.
    Type: Grant
    Filed: January 22, 1986
    Date of Patent: March 13, 1990
    Assignee: Temple University-of the Commonwealth System of Higher Education
    Inventors: Robert W. Colman, Alvin H. Schmaier